drugset / Trial / NCT06422767

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

NCT06422767

Phase 1 Completed 46 enrolled GlaxoSmithKline PPD Development, LP · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the effect of a single dose of bepirovirsen on the QT interval corrected by Fridericia's formula (QTcF) as compared to placebo. The data generated will be used to model the relationship between bepirovirsen concentration and QTcF.

Timeline

Start
2024-07-18
Primary completion
2025-04-28
Completion
2025-04-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bepirovirsen Antisense oligonucleotide Subcutaneous